NCT01514188Phase 2Completed

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Study sponsor: ImmunityBio, Inc. · IBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2014-04-09Actual
Enrollment · participants126Actual
Source updated2024-05-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview